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ABSTRACT 
Candida is one of the most frequent pathogens of bloodstream infections, which is 
associated with high morbidity and mortality rates. Rapid immunological detection methods 
are essential in the early diagnosis of candidemia. Anti-mannan is one of host-derived 
biomarkers against cell wall components of Candida. We conducted this study to evaluate 
the diagnostic performance of two anti-mannan assays (IgM, IgG) for candidemia through 
the analysis of 40 candidemia patients, 48 participants with Candida colonization and 213 
participants with neither Candida colonization nor Candida infections (13 patients with other 
bloodstream infections, 145 hospitalized patients and 55 healthy controls). The performance 
of the two assays were evaluated by calculating their sensitivity and specificity. The sensitivity 
ranged from 0.78 to 0.80 for the IgM assay and 0.68 to 0.75 for the IgG assay. The specificity 
ranged from 0.97 to 0.98 for the IgM assay and 0.91 to 0.94 for the IgG assay. The diagnostic 
performance of the anti-mannan IgM assay was better than that of IgG, with higher sensitivity 
and specificity. Combining the two assays (positive results of single or both assays are both 
considered as positive) could improve the sensitivity up to 0.93 (0.79-0.98) and only slightly 
reduce the specificity (0.93(0.89-0.95)). The anti-mannan IgM, IgG assays are rapid and 
cost-effective assays that may be probably useful in the diagnosis of candidemia.
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INTRODUCTION
Candida is one of the leading causes of healthcare-associated bloodstream 
infections. Owing to the advances in medical technology, the application of invasive 
procedures is becoming more and more extensive, increasing significantly the 
burden of Candida infections, especially in critically ill patients1,2. Early initiation 
of effective antifungal therapy was essential to improve the outcome of patients, 
while misdiagnosis or delay in diagnosis of candidemia could result in substantial 
morbidity and mortality (as high as 46–75%)3, so the early diagnosis of candidemia 
is of great value. 
Blood cultures are the gold standard of candidemia’s diagnosis. The current 
guidelines provided by the European Society for Clinical Microbiology and 
Infectious Diseases (ESCMID) and the Infectious Diseases Society of America 
(IDSA) have shown that it is essential to draw at least two pairs of blood cultures 
for the diagnosis of candidemia. The frequency recommended was daily and the 
incubation period was at least 5 days. When all these recommendations are followed, 
sensitivity of blood cultures to detect Candida will be between 50–75%4,5. The 
sensitivity will further decrease when detecting patients who have neutropenia or 
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previous antifungal treatment4,5. In addition, its turnaround 
time was limited so it cannot be considered as an early 
diagnostic technique. Regarding the clinical use of some 
biomarkers, B-D-glucan, mannan and anti-mannan are 
recommended with levels of evidence being II (second) 
according to ESCMID guidelines for Candida diseases6.
The Dynamiker Candida anti-mannan IgM and IgG 
assays are new enzyme-linked immunosorbent assays 
(ELISA) designed to rapidly identify antigens from 
Candida’s cell wall in serum samples. This study evaluated 
the performance of two different antibody isotypes for 
diagnosis of candidemia. 
MATERIALS AND METHODS
Study population
This study was approved by the Ethics Committee of the 
West China Hospital, (The Ethics Committee of West China 
Hospital, Nº 75, 76). To assess the diagnostic performance 
of the new anti-mannan IgM, IgG antibody assays, three 
groups of cases were enrolled: (1) Culture-confirmed 
candidemia, (2) Candida colonization without infection, 
(3) Neither Candida colonization nor infections. 
Candidemia was defined as the presence of one or more 
Candida species in the bloodstream. Its diagnostic criteria 
were at least one positive blood culture that yielded at 
least one of the Candida species in patients with consistent 
clinical manifestations. The exclusion criteria were as 
follow: neutropenia (total leukocyte count ≤ 500/mm3), 
pregnancy, autoimmune diseases, recent or ongoing 
immunosuppressive or antifungal therapy, significantly 
abnormal immune function. The blood cultures were 
processed by the BacTAlert® Virtuo® (bioMérieux, Marcy 
l’Etoile, France) system. All the specimens with positive 
results of blood cultures were identified on microscopy and 
subcultured on blood agar and chocolate agar for 48 h at 
35 °C under aerobic conditions. Candida spp. isolated from 
blood samples underwent identification by MALDI-TOF 
mass spectrometry. 
Candida colonization was defined as the recovery of 
Candida spp. from nonsterile and noncontiguous sites 
including mouth, throat, bronchus, skin and urethra. In the 
present study, we only enrolled cases who have Candida 
colonization in the upper respiratory tract because it is the 
most common colonization site. The exclusion criteria were: 
positive blood cultures for Candida; neutropenia; antifungal/
immunosuppressive therapy; positive (1-3)-β-D-Glucan. 
In total, there were 213 cases with neither colonization 
nor infections, 48 with Candida colonization and 40 
with candidemia in our study. Among the cases with 
neither Candida colonization nor infections, 55 of them 
were healthy controls randomly selected from the health 
examination center of the West China hospital, 158 were 
hospitalized patients, of whom 13 had other bloodstream 
infections. The 13 patients included 4 with Staphylococcus 
spp., 2 with Enterobacteria spp., 1 with Enterococcus spp., 
1 with Talaromyces (Penicillium) marneffei, and 5 with 
Cryptococcus spp. infection. None of them had neutropenia, 
recent or ongoing immunosuppressive therapy or antifungal 
therapy. 
The baseline characteristics of the 40 candidemia 
patients were presented in Table 2, while characteristics of 
control group 1 (neither Candida colonization nor infections 
group) and control group 2 (Candida colonization group) 
were presented in Table 3.
ELISA assay
The new anti-mannan IgM and IgG assays (Dynamiker 
Biotechnology, Tianjin, China) were performed strictly 
according to the manufacturer’s instructions. The 
Table 1 - Accuracy indices of the Candida anti-mannan IgM, IgG assays for candidemia.
Diagnostic parameter
Value of different anti-mannan antibody isotypes 
anti-mannan IgM anti-mannan IgG anti-mannan IgM+IgG

























aUndetermined results (80-120 AU/mL) were considered as negative results; bUndetermined results were considered as positive 
results. CI- confidence interval.
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recommended cut-off values are 120 AU/mL for both 
assays; 80 to 120 AU/mL is considered as undetermined 
results. All the data were analyzed anonymously and only 
routine diagnostic samples were used in this study, having 
no influence in therapeutic decisions. 




Age Sex Underlying condition
Time of 
incubationa









1 30 F Heart failure 1.58 319.21 P 189.91 P
2 30 M Acute pancreatitis 2 51.56 N >500 P
3 29 M Hematological system disease 0.95 217.52 P 147.56 P
4 71 M Postoperative infection 1.5 150.88 P >500 P
5 22 M Aplastic anemia 0.7 190.33 P 28.16 N
6 45 F Chronic hepatitis B 0.81 293.45 P 336.08 P
7 0 F Postoperative infection 1.16 39.80 N >500 P
8 48 M Acute pancreatitis 2 156.90 P 425.57 P
9 66 F Chronic renal failure 0.38 135.45 P 485.47 P
10 0 F Intestinal fistula 2 27.38 N >500 P
11 66 F Heart disease 1.12 173.98 P 133.81 P
12 78 M Intracranial infection 1.34 284.13 P 212.53 P
13 46 M Heart disease 2 132.60 P 198.82 P
14 31 M Acute pancreatitis 1.12 350.07 P 131.89 P
15 50 M Cholecystolithiasis 3.29 30.30 N 199.61 P
16 40 M Trauma 1.7 54.87 N >500 P
17 68 M Intestinal obstruction 1.5 >500 P 123.23 P
18 63 M Chronic obstructive pulmonary 
diseases
1.29 22.67 N >500 P
19 76 M Esophageal stricture 1.75 257.64 P 382.81 P
20 61 F Arthritis 1.18 191.80 P 208.57 P
21 64 F Trauma 1.17 186.36 P 128.76 P
22 75 F Abnormal liver function 0.25 >500 P 23.94 N
23 17 M Trauma 0.45 >500 P 23.21 N
24 42 F Acute pancreatitis 1.63 83.02 I 176.67 P
25 79 M Intestinal obstruction 1.88 >500 P 29.20 N
26 44 M Pulmonary infection 2.33 >500 P 61.04 N
27 44 F Hepatic abscess 0.71 58.41 N 92.99 I
28 48 M Trauma 0.8 96.98 I 264.82 P
29 35 M Abnormal liver function 2.2 >500 P 46.76 N
30 20 M Trauma 1.38 359.06 P 199.61 P
31 51 M Cerebral hemorrhage 0.7 84.81 I >500 P
32 33 F Acute pancreatitis 0.87 54.20 N 181.47 P
33 49 F Intestinal obstruction 1.58 490.59 P 345.08 P
34 63 M Heart disease 2.29 28.68 N 20.58 N
35 60 M Trauma 0.46 288.87 P >500 P
36 39 M Anemia 0.88 380.88 P 244.82 P
37 62 M None 1.17 244.42 P >500 P
38 56 M Gastrointestinal perforation 1.12 141.06 P >500 P
39 37 M Acute pancreatitis 2.33 337.44 P 143.19 P
40 59 F Arterial embolism of lower 
extremities 
1.75 42.64 N 28.28 N
aTotal incubation time to get a positive result of blood cultures; F = female; M = male; P = positive; N = negative.
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Statistical analysis
To illustrate the diagnostic performance of the assays, 
sensitivity (percentage of correctly identified candidemia) 
and specificity (percentage of correctly eliminated 
candidemia) were calculated. Specificity is calculated 
separately for control group 1, control group 2, and overall 
(control group 1 plus control group 2). GraphPad Prism 
(version 8.0.1; GraphPad Software, La Jolla, California, 
USA) was used to illustrate the antibody concentration data. 
RESULTS
Diagnostic performance of the anti-mannan IgG ELISA 
assay
Serum samples of 40 candidemia patients and 261 
controls were tested. Among the 40 candidemia patients, 
anti-mannan IgG were positive in 13/19 of candidemia 
patients with C. albicans infection, 6/8 with C. tropicalis, 
4/6 with C. parapsilosis, 2/5 with C. glabrata, 1/1 with 
C. krusei and 1/1 with C. lusitaniae. As for the undetermined 
results, they were considered to be positive and negative, 
respectively. If the undetermined results were considered as 
positive results, the IgG ELISA assay had a sensitivity of 0.75 
(0.58-0.87) and an overall specificity of 0.91 (0.87-0.94). 
If the undetermined results were considered negative, the 
IgG ELISA assay had a sensitivity of 0.68 (0.51-0.81) and 
an overall specificity of 0.94 (0.90-0.97) (Table 1). The 
specific concentrations of anti-mannan IgG were shown in 
Table 2 and Figure 1.
Diagnostic performance of anti-mannan IgM ELISA 
assay
Anti-mannan IgM were positive in 17/19 of candidemia 
patients with C. albicans, 5/8 with C. tropicalis, 4/6 with 
C. parapsilosis, 3/5 with C. glabrata 1/1 with C. krusei, 
Table 3 - Characteristics of control group 1 (without colonization) 






Median age, y (range) 44(31-52) 69 (63-75)
Gender (men/women) 109/104 30/18
Cardiovascular disease 31/213 6/48
Renal disease 20/213 4/48
Lung disease 9/213 19/48
Brain disease 29/213 8/48
Neurological disease 3/213 -
Hypertension 4/213 3/48
Biliary tract disease 9/213 2/48
Trauma 7/213 2/48
Fever 1/213 1/48
Digestive tract disease 19/213 1/48
Endocrine disease 4/213 -
Eye diseases 3/213 -
Bone disease 6/213 -
others 13/213 2/48
Healthy control 55/213 -
Figure 1 - The concentration of anti-mannan IgG and IgM antibodies in candidemia patients and controls. The dotted lines are the 
cut-off values of the assays (80AU/mL and 129AU/mL); the continuous lines are the median of the concentrations of the antibodies 
in each group
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1/1 with C. lusitaniae. If the undetermined results were 
considered as positive results, the IgM ELISA assay 
had a sensitivity of 0.80 (0.64-0.90) and a specificity 
of 0.97 (0.94-0.99). If the undetermined results were 
considered as negative results, the IgM ELISA assay 
had a sensitivity of 0.78 (0.61-0.89) and a specificity of 
0.98 (0.95-0.99) (Table 1). The specific concentrations 
of anti-mannan IgM were shown in Table 2 and Figure 1.
Diagnostic performance of the combined detection of 
the two assays
In the combined detection of IgG and IgM assays, serum 
samples with positive result (>120 AU/mL) of single or 
both assays were regarded as positive. Anti-mannan IgG 
and/or IgM were positive in 19/19 of candidemia patients 
with C. albicans infection, 7/8 with C. tropicalis, 5/6 with 
C. parapsilosis, 4/5 with C. glabrata, 1/1 with C. krusei, 1/1 
with C. lusitaniae. The sensitivity of the combined detection 
of two assays for diagnosing candidemia was 0.93 (0.79-0.98) 
and the specificity was 0.93 (0.89-0.95) (Table 1).
DISCUSSION 
Candidemia is one of the most common bloodstream 
fungal infections whose diagnosis is based mainly on blood 
cultures7. However, blood cultures lack sensitivity (ranging 
from 21% to 71% in different studies)8 and its turnaround 
time is limited. As is known, even a mere 12 hours of 
diagnostic delay may expose infected individuals to a higher 
risk of disability and mortality9, so the timely diagnosis is 
of cardinal importance. 
Parra-Sánchez et al.10 indicated that the sensitivity of 
the C. albicans germ-tube specific IgG antibody assay 
ranged from 61.1% to 85.7% and the specificity ranged from 
75.8% to 80.3%. Mattsby-Baltzer et al.11 study reported 
that IgG
2
 anti-phosphopeptidomannan antibody is another 
biomarker with 88% sensitivity and 94% specificity in 
invasive candidiasis, but no IgG2 antibody response was 
observed in C. parapsilosis and C. albicans infections. 
White et al.12 described that the sensitivity and specificity of 
a (1-3)-β-D-Glucan (D-BDG) assay were 90.7% and 73.4% 
in the diagnosis of invasive fungal disease, when optimal 
positivity threshold was 70 pg/mL. Alam et al.13 reinforced 
the diagnostic value of semi-nested PCR (snPCR), which can 
detect DNA of different Candida species in serum samples of 
over 50% of the clinically suspected patients without positive 
blood cultures, while the combination of mannan and D-BDG 
is necessary to eliminate false positive reactions. 
Antibodies against constituents of Candida are also 
sensitive biomarkers. As is known, antibodies to Candida 
class IgA, IgM, IgG and IgE14-16, and different antibody 
isotypes differ in diagnostic performance. A study has 
shsown that Candida albicans could significantly decrease 
the secretion of IgG in a dose-dependent manner while 
enhancing IgM16. In addition, the difference in antibody 
levels between patients and healthy controls is more 
significant for anti-Candida receptor 3-related protein IgM 
than for IgG17, and atopic dermatitis patients were found 
to have abnormalities in the production of IgG antibodies 
against Candida albicans18. To sum up, IgM is probably 
more useful than IgG for the diagnosis of candidemia. 
In studies with different designs and populations, the 
clinical value of anti-mannan assays in the diagnosis of 
Candida infection had variable sensitivity (40% to 70%) 
and specificity (50% to 80%)19-21. Differences in diagnostic 
performance may be attributed to inclusion and exclusion 
criteria, different sample structure including number of 
cases enrolled, grouping mode, baseline characteristics and 
distribution of isolated Candida spp. In Mikulska et al.22 
meta-analysis, the sensitivity and specificity of the anti-
mannan assays for invasive candidiasis were 59% and 86%, 
and the sensitivity and specificity for a combined mannan/
anti-mannan assay were 83% and 86%. Meta-analysis can 
solve the problem of small sample size, yet it may suffer 
from publication bias. Many of these studies did not mention 
which isotype of antibody was used.
In the present study, we evaluated the diagnostic 
performance of a new anti-mannan IgM and IgG assays for 
candidemia. All the enrolled cases were candidemia patients 
without significantly abnormal immune function and this 
is the most likely explanation for the better diagnostic 
performance (higher sensitivity) than in other studies. 
Regarding the discordant results, only three confirmed that 
candidemia patients had negative results in both assays, 
including one with C. tropicalis, one with C. parapsilosis 
and one with C. glabrata. Anti-mannan IgM assay had a 
better diagnostic performance than the IgG assay, with 
higher sensitivity and specificity. 
The combined assays in our study had relatively high 
sensitivity and there was a high concordance with the 
infections status. Among all the 40 candidemia patients, 
the serum sample collection of 23 candidemia patients 
took place before getting the positive results of blood 
cultures. We obtained positive detection of IgM antibodies 
in 21 of them, while IgG was detected in 15 of them. In 
the combined detection of IgG and IgM, only one of these 
23 patients (infected with C. parapsilosis) had both, IgG 
and IgM negative antibodies. The combined assays can help 
to detect infections earlier because they can be positive as 
long as 4 days prior to blood cultures. Chumpitazi et al.23 
found that mannan is also a biomarker appearing early in 
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the development of candidemia. However, its specificity 
was 86% and its sensitivity was 77% in the meta-analysis. 
Although both, the sensitivity and specificity of the assays 
in our study showed better diagnostic performances, there 
were still several nonspecific results in the control groups, 
some of which had high antibody titers. According to the 
manufacturer’s instructions, these assays are qualitative 
rather than quantitative with cut-off values of 80 AU/mL 
and 120 AU/mL, so that positive or negative results are 
more valuable for clinical practice. In Clancy et al.24 review, 
invasive candidiasis patients with negative blood cultures 
were called the “missing 50%”, which is one of the possible 
reasons for the nonspecific results with high titers especially 
in patients with Candida colonization. However, whether 
some of the patients without any evidence of infection 
had positive result is still uncertain. From the results, we 
suggested that candidemia cannot be judged only according 
to high titers of anti-mannan IgG or IgM. A correct 
diagnosis must be made on the basis of suggestive clinical 
symptoms, presence of risk factors for candidemia (such 
as abdominal surgery, central venous catheter, mechanical 
ventilation, etc). Unselected screening of anti-mannan for 
Candida infections in similar settings is inappropriate, while 
using anti-mannan as a complementary test to blood culture 
results may be preferred in clinically suspected candidemia 
patients and cases with high risk based on our study results. 
CONCLUSION
Our study has shown that anti-mannan IgM and IgG 
assays are useful to assist clinicians in making an earlier 
diagnosis of candidemia and differentiating Candida 
colonization from candidemia in patients without 
significantly abnormal immune function. The tests have 
shown a high negative predictive value (>85%) and can be 
used to rule out infections, as part of diagnostic strategies to 
establish the absence of candidemia, reducing the unwarrant 
use of antifungal agents in patients. 
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